On : 26 june 2025
• As of 2023, the global Fatty Liver Drugs Market is valued at approximately USD 20.14 billion and is projected to reach USD 31.78 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.20% over the forecast period. This growth is fueled by increasing awareness, technological advancement in diagnostics, rising incidence of obesity, sedentary lifestyle, and growing investments in drug development for liverrelated conditions.
Email:
• There are substantial market opportunities due to the development of precision medicine techniques and non-invasive diagnostic biomarkers. Early detection and disease monitoring are being enhanced by innovations such as imaging-based diagnostics (FibroScan, MRI-PDFF) and serum biomarkers (ALT, CK-18). When approved, a strong pipeline of treatments that target fibrosis, inflammation, and lipid metabolism, like obeticholic acid (Intercept Pharmaceuticals) and resmetirom (Madrigal Pharmaceuticals), could revolutionize the therapeutic landscape.
Email: help@intelmarketresearch.com +91 9169164321
•Alcoholic Fatty Liver Disease (AFLD)
•Non-Alcoholic Fatty Liver Disease (NAFLD)
•Non-Alcoholic Steatohepatitis (NASH)
